BofA reiterates Sarepta stock Underperform on regulatory risk By Investing.com

Sarepta will submit supplemental NDAs by end-April to seek conversion of AMONDYS 45 and VYONDYS 53 accelerated approvals to traditional approval, with the FDA allowing inclusion of ESSENCE confirmatory and real-world evidence data. Shares trade at $16.71 (down 79% from the 52-week high); BofA reiterated an Underperform with a $19 PT while Jefferies and Mizuho hold $30/$31 bullish targets and InvestingPro cites a $22.85 fair value. BofA flags ongoing regulatory risk, is risk-adjusting PMO revenues from 2027, and Sarepta has initiated a sirolimus + ELEVIDYS trial to reduce acute liver injury; confirmatory readouts (Exondys dose-findings) expected H2.

Analysis

The immediate market framing is a binary regulatory event, but the economically decisive variable is commercial survivability across multiple geographies and payer tiers — not just whether an approval label is converted. If the label is sustained on a narrower or conditional basis, ramp rates and price concessions will matter more than headline approval, favoring players that control manufacturing scale and cost-per-dose. Expect 6–9 month volatility as regulators digest mixed clinical and real-world signals; RWE-driven approvals add variance and make outcomes path-dependent rather than purely binary.

Second-order beneficiaries include AAV fill/finish and analytical testing vendors: a partial preservation of market access preserves multi-year manufacturing bookings that can drive EBITDA leverage at public CMOs. Conversely, small-cap competitors with single-product dependencies face the largest downside if payers adopt stringent utilization controls—this can compress sector valuations even if one company stabilizes. Separately, the elevated risk appetite signaled by large discretionary longs (e.g., NVDA-style flow into concentrated winners) can transiently compress hedger supply for bisected biotech positions, amplifying short squeezes and option skew.

The two dominant regime risks are (1) a definitive negative regulatory ruling or aggressive label with access restrictions that materially reduces peak revenue (low-probability, high-impact) and (2) a successful mitigation of safety signals via adjunct therapy or dosing changes that preserves addressable market (medium-probability, multi-year value). These map to trades that prefer defined-risk asymmetric upside ahead of readouts, and hedged downside exposure if you want carry through the regulatory window. Market consensus currently prices a high variance; my read is that the probability mass is wider than the market assumes — more room for both a sharp relief rally and a drawn-out revenue revision cycle.

Key Decisions for Investors

• Directional defined-risk long (SRPT): Buy a 12–18 month call spread (e.g., buy Jul 2026 25C / sell Jul 2026 45C) sized to risk no more than 1–2% of portfolio. Rationale: asymmetric upside if regulatory pathway is clarified favorably and real-world data supports label; max loss = premium, upside ~2–3x if sentiment normalizes.
• Hedged manufacturing exposure (CTLT or TMO): Buy outright 6–12 month exposure to Catalent (CTLT) or Thermo Fisher (TMO) as optionality on sustained AAV demand. Position size modest (1–2% portfolio), target 30–50% upside if multiple re-rating occurs; hedge by shorting 0.5x notional of SRPT equity to neutralize pure biotech beta.
• Event-protection short (SRPT): Buy near-term puts (3–6 month) as insurance if you own other high-beta biotech names or CTMOs. Use puts to cap downside exposure — expect these to pay off in a failure scenario where shares gap lower; treat as tail hedges sized to limit portfolio drawdown to pre-defined tolerance.
• Pair trade for volatility compression: Long SRPT call spread (12–18 months) / Short a small-cap DMD peer or single-product gene therapy company (equal notional). This expresses view that regulatory salvage preserves manufacturing revenue while punishing peers without diversification; target 1.5–2.0x reward-to-risk and monitor catalyst calendar (dose-finding and readouts).